Ignite Creation Date:
2025-12-25 @ 2:34 AM
Ignite Modification Date:
2026-03-01 @ 4:12 PM
Study NCT ID:
NCT02089334
Status:
TERMINATED
Last Update Posted:
2020-06-30
First Post:
2014-03-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Sponsor:
Rexahn Pharmaceuticals, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic Renal Cell Cancer | View |